Published in J Virol on September 01, 1998
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol (2004) 2.42
Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol (2000) 2.41
Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol (1999) 2.34
The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol (2005) 2.13
Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun (1999) 1.86
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
Measles virus for cancer therapy. Curr Top Microbiol Immunol (2009) 1.56
A ferret model of canine distemper virus virulence and immunosuppression. J Virol (2003) 1.55
Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol (2006) 1.54
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol (2000) 1.48
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun (2006) 1.43
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol (2007) 1.40
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther (2009) 1.35
Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol (2006) 1.35
A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol (2007) 1.34
A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol (1999) 1.33
Roles of macrophages in measles virus infection of genetically modified mice. J Virol (2001) 1.33
A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol (2003) 1.28
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology (2008) 1.24
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology (2009) 1.23
CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. Infect Immun (2005) 1.22
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Innate STAT1-dependent genomic response of neurons to the antiviral cytokine alpha interferon. J Virol (2005) 1.21
Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. J Virol (2004) 1.21
Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol (2007) 1.20
In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol (2000) 1.20
Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J Virol (2002) 1.18
Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther (2008) 1.18
Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther (2008) 1.17
Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin Exp Immunol (2001) 1.16
Emerging roles and new functions of CD46. Springer Semin Immunopathol (2005) 1.16
Imaging of disease dynamics during meningococcal sepsis. PLoS One (2007) 1.14
Attenuated measles virus as a vaccine vector. Vaccine (2007) 1.13
Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Med Microbiol Immunol (2010) 1.13
Olfactory nerve--a novel invasion route of Neisseria meningitidis to reach the meninges. PLoS One (2010) 1.10
Cytokine determinants of viral tropism. Nat Rev Immunol (2009) 1.10
Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One (2009) 1.08
Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J Clin Invest (2003) 1.07
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proc Natl Acad Sci U S A (2005) 1.05
Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. J Virol (2006) 1.02
Rational attenuation of a morbillivirus by modulating the activity of the RNA-dependent RNA polymerase. J Virol (2005) 1.01
Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine (2010) 1.00
Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol (2001) 1.00
Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis (2007) 0.99
Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol (2002) 0.98
Making it to the synapse: measles virus spread in and among neurons. Curr Top Microbiol Immunol (2009) 0.96
Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther (2009) 0.96
Alpha/beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism. J Virol (2007) 0.96
Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res (2010) 0.96
Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther (2013) 0.95
Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine (2009) 0.94
Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther (2012) 0.94
hsp72, a host determinant of measles virus neurovirulence. J Virol (2006) 0.94
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol (2012) 0.92
Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J Virol (2009) 0.91
High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice. J Virol (2006) 0.91
Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med (2015) 0.90
Human receptor for measles virus (CD46) enhances nitric oxide production and restricts virus replication in mouse macrophages by modulating production of alpha/beta interferon. J Virol (2000) 0.89
DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther (2013) 0.88
Antiviral type I and type III interferon responses in the central nervous system. Viruses (2013) 0.88
Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals. Clin Vaccine Immunol (2006) 0.87
Productive measles virus brain infection and apoptosis in CD46 transgenic mice. J Virol (2000) 0.87
Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. PLoS One (2012) 0.87
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One (2012) 0.86
Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9. J Virol (2014) 0.86
Type I interferon signaling limits reoviral tropism within the brain and prevents lethal systemic infection. J Neurovirol (2011) 0.85
The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Mol Ther (2013) 0.84
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (2015) 0.83
The F gene of the Osaka-2 strain of measles virus derived from a case of subacute sclerosing panencephalitis is a major determinant of neurovirulence. J Virol (2010) 0.83
Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccin Immunother (2013) 0.83
Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol Ther (2013) 0.83
Chlamydial infection increases gonococcal colonization in a novel murine coinfection model. Infect Immun (2011) 0.82
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
Altered virulence of vaccine strains of measles virus after prolonged replication in human tissue. J Virol (1999) 0.82
Expression of the Sendai (murine parainfluenza) virus C protein alleviates restriction of measles virus growth in mouse cells. Proc Natl Acad Sci U S A (2011) 0.82
Vaccine platform recombinant measles virus. Virus Genes (2017) 0.81
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol (2015) 0.81
Virus-heat shock protein interaction and a novel axis for innate antiviral immunity. Cells (2012) 0.80
Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells. Virus Res (2012) 0.80
Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother (2013) 0.80
Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5. Virol J (2012) 0.79
CD46 transgenic mouse model of necrotizing fasciitis caused by Streptococcus pyogenes infection. Infect Immun (2009) 0.79
Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine (2012) 0.79
Homeostatic interferon expression in neurons is sufficient for early control of viral infection. J Neuroimmunol (2014) 0.78
The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother (2016) 0.77
Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus. Vaccines (Basel) (2015) 0.77
CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy. Hum Gene Ther (2014) 0.77
An immune competent mouse model for the characterization of recombinant measles vaccines. Hum Vaccin Immunother (2014) 0.77
Oncolytic virotherapy for ovarian cancer. Oncolytic Virother (2012) 0.77
Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity. Immunology (2000) 0.77
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Simplified mammalian DNA isolation procedure. Nucleic Acids Res (1991) 12.56
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature (1992) 9.01
Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell (1988) 4.90
Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol (1991) 4.27
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell (1990) 3.70
Mechanism of suppression of cell-mediated immunity by measles virus. Science (1996) 3.55
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med (1997) 2.90
The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J (1997) 2.71
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol (1997) 2.67
A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J (1998) 2.48
Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology (1997) 2.01
The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells. Virology (1996) 1.95
Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci U S A (1996) 1.89
Receptor usage and differential downregulation of CD46 by measles virus wild-type and vaccine strains. Proc Natl Acad Sci U S A (1995) 1.89
Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci U S A (1995) 1.86
Experimental measles. I. Pathogenesis in the normal and the immunized host. Virology (1997) 1.83
A transgenic mouse model for measles virus infection of the brain. Proc Natl Acad Sci U S A (1997) 1.62
Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA. J Infect Dis (1988) 1.59
Differential downregulation of CD46 by measles virus strains. J Virol (1995) 1.57
Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections. J Virol (1996) 1.51
Age dependence of viral expression: comparative pathogenesis of two rodent-adapted strains of measles virus in mice. Infect Immun (1974) 1.51
Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol (1996) 1.51
Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology (1992) 1.47
Measles virus-induced immune suppression in the cotton rat (Sigmodon hispidus) model depends on viral glycoproteins. J Virol (1997) 1.45
Antigenic determinants of measles virus hemagglutinin associated with neurovirulence. J Virol (1994) 1.43
Fatal measles infection in marmosets pathogenesis and prophylaxis. Infect Immun (1980) 1.43
A method for the generation of YAC transgenic mice by pronuclear microinjection. Nucleic Acids Res (1993) 1.40
Mapping of the primary binding site of measles virus to its receptor CD46. J Biol Chem (1997) 1.32
Identification and quantification of complement regulator CD46 on normal human tissues. Immunology (1993) 1.28
Measles virus infections in rodents. Curr Top Microbiol Immunol (1995) 1.25
Receptor (CD46) modulation and complement-mediated lysis of uninfected cells after contact with measles virus-infected cells. J Virol (1996) 1.19
Susceptibility to measles virus-induced encephalitis in mice correlates with impaired antigen presentation to cytotoxic T lymphocytes. J Virol (1993) 1.12
Subacute sclerosing panencephalitis. Semin Pediatr Neurol (1996) 1.08
Appendix: measles virus antigenome and protein consensus sequences. Curr Top Microbiol Immunol (1995) 1.06
Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics (1992) 1.06
Measles associated hepatobiliary disease: an overview. Infection (1993) 1.04
Production of transgenic mice with yeast artificial chromosomes. Trends Genet (1997) 1.03
Monkeys in measles research. Curr Top Microbiol Immunol (1995) 1.02
Selective expression of a subset of measles virus receptor-competent CD46 isoforms in human brain. Virology (1996) 0.99
Identification of interferon-resistant subpopulations in several strains of measles virus: positive selection by growth of the virus in brain tissue. J Virol (1990) 0.93
CD46 expression does not overcome the intracellular block of measles virus replication in transgenic rats. J Virol (1997) 0.92
Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection. Eur J Immunol (1997) 0.92
Generation of transgenic mice with yeast artificial chromosomes. Cold Spring Harb Symp Quant Biol (1993) 0.89
Effect of interferon-alpha on measles virus replication in human peripheral blood mononuclear cells. APMIS (1992) 0.88
Characterization of the promoter region of the membrane cofactor protein (CD46) gene of the human complement system and comparison to a membrane cofactor protein-like genetic element. J Immunol (1993) 0.82
Quantification of measles virus by a virus receptor-dependent and haemagglutinin-specific T cell stimulation assay. J Immunol Methods (1995) 0.81
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J (1995) 6.94
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J (1996) 6.66
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 6.13
Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 5.07
Molecular and cellular physiology of intracellular calcium stores. Physiol Rev (1994) 5.04
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol (1991) 4.27
Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature (1996) 4.25
Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol (2001) 3.65
Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell (1998) 3.59
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
c-jun is essential for normal mouse development and hepatogenesis. Nature (1993) 3.43
Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev (1995) 3.41
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol (1989) 3.20
cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol (1989) 3.20
A crucial role for B cells in neuroinvasive scrapie. Nature (1998) 3.19
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med (1986) 2.94
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev (1992) 2.77
Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med (1988) 2.75
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Ilizarov treatment of tibial nonunions with bone loss. Clin Orthop Relat Res (1989) 2.71
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol (1997) 2.67
The regulators of complement activation (RCA) gene cluster. Adv Immunol (1989) 2.63
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell (1989) 2.54
Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci (2000) 2.54
A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J (1998) 2.48
The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol (1995) 2.47
Control of the complement system. Adv Immunol (1996) 2.43
PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med (1998) 2.40
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Retracted Infectious measles virus from cloned cDNA. EMBO J (1990) 2.36
Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci U S A (1983) 2.30
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Targeted mutation of the CREB gene: compensation within the CREB/ATF family of transcription factors. Proc Natl Acad Sci U S A (1994) 2.24
Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature (1996) 2.24
New variant of Creutzfeldt-Jakob disease in a 26-year-old French man. Lancet (1996) 2.20
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A (1995) 2.19
High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med (1994) 2.18
Post-exposure prophylaxis after accidental prion inoculation. Lancet (1997) 2.15
Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science (2000) 2.15
Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell (1989) 2.14
Prion research: the next frontiers. Nature (1997) 2.13
Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron (2000) 2.13
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med (1985) 2.12
Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U S A (1985) 2.11
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A (1994) 2.08
PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature (1997) 2.08
The amplification of ribosomal RNA genes involves a rolling circle intermediate. Proc Natl Acad Sci U S A (1973) 2.07
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. Nat Med (1997) 2.07
Induction of the PML protein by interferons in normal and APL cells. Leukemia (1995) 2.05
Ryanodine receptors: how many, where and why? Trends Pharmacol Sci (1993) 2.04
No propagation of prions in mice devoid of PrP. Cell (1994) 2.02
Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology (1995) 1.96
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain (2004) 1.96
Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci U S A (1996) 1.89
The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol (2001) 1.88
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology (2005) 1.88
Measles virus envelope glycoproteins hetero-oligomerize in the endoplasmic reticulum. J Biol Chem (2001) 1.87
Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci U S A (1995) 1.86
A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J (1998) 1.86
Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases) Brain Pathol (1995) 1.86
Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J (2001) 1.85
Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem (2000) 1.84
Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J Virol (1986) 1.84
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci (1995) 1.83
Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 1.82
A novel expression selection approach allows precise mapping of the hepatitis B virus enhancer. Nucleic Acids Res (1985) 1.82
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Retracted Functional and nonfunctional measles virus matrix genes from lethal human brain infections. J Virol (1991) 1.82
Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci U S A (1999) 1.81
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Inositol 1,4,5-trisphosphate induces calcium release from sarcoplasmic reticulum of skeletal muscle. Nature (1985) 1.78
Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology (1991) 1.77
Molecular characterization of the Ss and Slp (C4) proteins of the mouse H-2 complex: subunit composition, chain size polymorphism, and an intracellular (PRO-Ss) precursor. J Immunol (1978) 1.75